American College of Medical Genetics and Genomics Practice Guidelines Support Lifelong Therapy to Manage Phenylketonuria (PKU)

American College of Medical Genetics and Genomics Practice Guidelines Support
Lifelong Therapy to Manage Phenylketonuria (PKU)

Recommend Drug Therapy, Such as Kuvan(R) (Sapropterin Dihydrochloride), for
Appropriate Patients

SAN RAFAEL, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) announced today that new practice guidelines issued by the
American College of Medical Genetics and Genomics (ACMG) support the need for
lifelong management of PHE levels in patients with phenylketonuria or PKU. The
new diagnosis and management guidelines were published online in Genetics In
Medicine's Advance Online Publication (AOP) service and provide the first
update to recommendations for therapy of PKU since the 2001 National
Institutes of Health Consensus statement.

The new guidelines state that treatment of PKU should be initiated as early as
possible and must be continued throughout adulthood and "lifelong," with a
goal of maintaining blood levels of phenylalanine (PHE) for all patients
between 120-360 umol/L. Patients treated from the early weeks of life with
initial good metabolic control, but who lose that control in later childhood
or adult life, may experience both reversible and irreversible
neuropsychiatric consequences.The guidelines also recommend changing the name
of the disease from PKU to phenylalanine hydroxylase deficiency (PAH
deficiency),a unifying nomenclature that reflects the continuous spectrum of
disease severity.The guidelines specifically note that for, appropriate
patients, use of Kuvan® (sapropterin dihydrochloride) should be considered to
help lower PHE.

According to the new guidelines, "The primary goal of therapy is to lower
blood PHE, and any interventions, including medications, or combination of
therapies that help to achieve that goal in an individual, without other
negative consequences, should be considered appropriate therapy."

Kuvan, the first and only prescription medication that helps patients lower
blood PHE levels, is recognized for its potential benefits with 25-50 percent
of PKU or PAH deficient patients cited as responsive to treatment with Kuvan.
PEG PAL is an experimental therapy in Phase 3 of clinical development with a
primary endpoint of PHE lowering, and a secondary endpoint of neurocognitive
benefit. The guidelines state that "an improvement in neuropsychiatric
symptoms or increase in PHE tolerance, without a decrease in blood PHE levels
in any patient, constitutes sufficient justification to continue therapy."

"We have made great strides in recent years in the understanding and
management of PKU. Thanks to the American College of Medical Genetics and
Genomics, we now know just how important it is for patients with PAH
deficiency to continue lifelong management of their condition," said Hank
Fuchs, M.D., Chief Medical Officer of BioMarin."BioMarin is committed to the
PKU community and is developing PEG PAL, a potential treatment option for
patients age 16 and older who are struggling to achieve and maintain blood PHE
levels within the recommended ranges.Treatments like Kuvan and the
development of new therapies are critical to helping patients with PKU or PAH
deficiency lead long, fulfilling lives."

Evidence for the new guidelines are drawn from two previous independent review
processes from the National Institutes of Health (2001) and the Agency for
Health Research and Quality (2012). The guidelines can be accessed online at:

About PKU or PAH Deficiency

Phenylketonuria (PKU) or phenylalanine hydroxylase (PAH) deficiency is a
genetic disorder affecting approximately 50,000 diagnosed patients in the
developed world and is caused by a deficiency of the enzyme phenylalanine
hydroxylase (PAH), this enzyme is required for the metabolism of phenylalanine
(PHE), an essential amino acid found in most protein-containing foods. If the
active enzyme is not present in sufficient quantities, PHE accumulates to
abnormally high levels in the blood and becomes toxic to the brain, resulting
in a variety of complications including severe intellectual disability,
seizures, tremors, behavioral problems and psychiatric symptoms. As a result
of newborn screening efforts implemented in the 1960s and early 1970s,
virtually all individuals with PKU or PAH deficiency under the age of 40 in
developed countries are diagnosed at birth and treatment is implemented soon
after. PAH deficiency can be managed with a PHE-restricted diet, which is
supplemented by low-protein modified foods and PHE-free medical foods;
however, the strict diet is difficult for most patients to adhere to the
extent needed for achieving adequate control of blood PHE levels.Kuvan, the
first and only prescription medicine of its kind, may help individuals with
PAH deficiency lower blood PHE levels when used in conjunction with a
PHE-restricted diet, more than the use of diet alone. To learn more about PAH
deficiency, please visit Information on this website is not
incorporated by reference into this press release. Some of the signs and
symptoms of high blood PHE include:

  *For infants and children: severe intellectual disability and developmental
    delay, skin rash (eczema), light-colored skin, eyes and hair
  *For teens and adults: lower intelligence, psychological and psychiatric
    symptoms like anxiety, depression and phobias, problems with memory and
    performing tasks (executive function), poor concentration and irritable
    mood among other things.
  *For pregnant women: increased risk for the baby's growing brain, including
    risk of intellectual disability, increased risk for a small head
    (microcephaly) and other problems such as a heart malformation (congenital
    heart defect) and poor overall growth (intrauterine growth retardation).
    This teratogenic effect of PHE on the developing fetus is called Maternal
    PKU syndrome.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme® (galsulfase) for MPS VI, a
product wholly developed and commercialized by BioMarin; Aldurazyme®
(laronidase) for MPS I, a product which BioMarin developed through a 50/50
joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride)
Tablets, for phenylketonuria (PKU), developed in partnership with Merck
Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse®
(amifampridine), which has been approved by the European Commission for the
treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates
include VIMIZIM™ (N-acetylgalactosamine 6-sulfatase), formally referred to as
GALNS, which successfully completed Phase 3 clinical development for the
treatment of MPS IVA, PEG PAL (PEGylated recombinant phenylalanine ammonia
lyase), which is currently in Phase 3 clinical development for the treatment
of PKU, BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is
currently in Phase 3 clinical development for the treatment of germline BRCA
breast cancer, BMN 701, a novel fusion of acid alpha glucosidase (GAA) with a
peptide derived from insulin like growth factor 2, which is currently in Phase
1/2 clinical development for the treatment of Pompe disease, BMN 111, a
modified C-natriuretic peptide, which is currently in Phase 1 clinical
development for the treatment of achondroplasia and BMN 190, a recombinant
human tripeptidyl peptidase-1 (rhTPP1) for the treatment of late-infantile
neuronal ceroid lipofuscinosis (CLN2), a form of Batten Disease. For
additional information, please visit Information on BioMarin's
website is not incorporated by reference into this press release.

Forward-Looking Statement
This press release contains forward-looking statements about the business
prospects of BioMarin Pharmaceutical Inc., including, without limitation,
statements about: the development of PEG PAL, an experimental therapy, for the
management of phenylketonuria or PKU. These forward-looking statements are
predictions and involve risks and uncertainties such that actual results may
differ materially from these statements. These risks and uncertainties
include, among others: results and timing of current and planned clinical
trials of PEG PAL; our ability to successfully manufacture PEG PAL; the
content and timing of decisions by the U.S. Food and Drug Administration and
other regulatory authorities concerning PEG PAL; and those risks that are
discussed in BioMarin's filings with the Securities and Exchange Commission,
including, without limitation, BioMarin's 2012 Annual Report on Form 10-K, and
our periodic reports on Form 10-Q and Form 8-K. Stockholders are urged not to
place undue reliance on forward-looking statements, which speak only as of the
date hereof. BioMarin is under no obligation, and expressly disclaims any
obligation to update or alter any forward-looking statement, whether as a
result of new information, future events or otherwise.

Vimizim™ is our trademark, and BioMarin^®, Naglazyme^®, Kuvan^®, Firdapse^®
are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme^® is a registered trademark of BioMarin/Genzyme LLC.

CONTACT: Investors
         Traci McCarty
         BioMarin Pharmaceutical Inc.
         (415) 455-7558
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo
Press spacebar to pause and continue. Press esc to stop.